Department of Biochemistry, Mashhad University of Medical Sciences, Razavi Khorasan, Mashhad, Iran.
Medical School, Islamic Azad University, Mashhad, Iran.
Curr Pharm Des. 2024;30(18):1386-1397. doi: 10.2174/0113816128291321240329050945.
Due to self-renewal, differentiation, and limitless proliferation properties, Cancer Stem Cells (CSCs) increase the probability of tumor development. These cells are identified by using CSC markers, which are highly expressed proteins on the cell surface of CSCs. Recently, the therapeutic application of CSCs as novel biomarkers improved both the prognosis and diagnosis outcome of colorectal Cancer. In the present review, we focused on a specific panel of colorectal CSC markers, including LGR5, ALDH, CD166, CD133, and CD44, which offers a targeted and comprehensive analysis of their functions. The selection criteria for these markers cancer were based on their established significance in Colorectal Cancer (CRC) pathogenesis and clinical outcomes, providing novel insights into the CSC biology of CRC. Through this approach, we aim to elevate understanding and stimulate further research for developing effective diagnostic and therapeutic strategies in CRC.
由于自我更新、分化和无限增殖的特性，癌症干细胞（CSC）增加了肿瘤发展的可能性。这些细胞是通过使用 CSC 标记物来识别的，这些标记物是 CSC 细胞表面高度表达的蛋白质。最近，CSC 作为新型生物标志物的治疗应用改善了结直肠癌的预后和诊断结果。在本综述中，我们重点关注了一组特定的结直肠 CSC 标记物，包括 LGR5、ALDH、CD166、CD133 和 CD44，它们对其功能进行了针对性和全面的分析。选择这些标记物的标准是基于它们在结直肠癌（CRC）发病机制和临床结果中的既定意义，为 CRC 的 CSC 生物学提供了新的见解。通过这种方法，我们旨在提高认识并激发进一步的研究，以开发 CRC 的有效诊断和治疗策略。
